PFE – Pfizer Inc.
Healthcare | Drug Manufacturers - General | Website
Quick Stats
Trend Overview
PFE is in a well-structured bull trend. All major signals are aligned: positive swing trend, rising momentum over 27 days, and trend strength confirmed by ADX at 84.7. This is the type of environment where trend-following strategies carry a structural edge.
The trend is your friend here. As long as momentum strength continues to hold or rise, the path of least resistance remains higher. Manage the trade with a trailing stop rather than a fixed target.
Options Signal Highlight
Latest PFE Reports
PFE Price Chart
Technical Trend Analysis
As of 21.08.2026 · Close: $28.07 · ATR14: $2.16
PFE is in a well-structured bull trend. All major signals are aligned: positive swing trend, rising momentum over 27 days, and trend strength confirmed by ADX at 84.7. This is the type of environment where trend-following strategies carry a structural edge.
The trend is your friend here. As long as momentum strength continues to hold or rise, the path of least resistance remains higher. Manage the trade with a trailing stop rather than a fixed target.
| Indicator | Signal | Detail |
|---|---|---|
| Swing Trend | ▲ Long | Primary directional bias |
| Momentum | ▲ Up · 27d | Strength: 0.87 – Rising |
| Trend Strength (ADX) | 84.7 – Strong | ADX38: 51.1 |
| Volatility (HV30) | 21.9% – Rising | HV90: 21.0% | HV180: 21.8% |
| Vola Compression | None | Normal range |
| MA Structure | Death Cross ✗ | Stack: Partially aligned (1/3) |
| EMA21 Distance | 0.72 ATR ↑ | EMA21: $26.19 |
| GD200 Extension | 3.7 ATR – Normal | GD20: 3.1 | GD50: 4.9 | GD100: 3.8 |
Monthly Performance History
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2010 | -1.41 | -5.70 | -3.44 | -2.15 | -9.04 | -4.85 | 5.38 | 3.91 | 5.51 | 1.39 | -6.46 | 4.85 | -3.59 |
| 2011 | 3.01 | 1.13 | 6.12 | 2.88 | 3.07 | -2.11 | -7.18 | 1.02 | -6.48 | 11.04 | 4.85 | 8.04 | 27.46 |
| 2012 | -2.59 | -0.79 | 5.41 | 1.33 | -3.05 | 6.35 | 4.52 | -0.31 | 4.49 | -0.66 | 2.85 | -0.07 | 18.53 |
| 2013 | 6.19 | -0.98 | 5.41 | 0.75 | -5.00 | 0.97 | 6.06 | -3.05 | 2.60 | 6.22 | 2.57 | -3.77 | 22.17 |
| 2014 | -0.17 | 5.82 | 0.44 | -2.08 | -4.04 | -0.12 | -3.75 | 1.79 | 1.06 | 2.71 | 4.10 | -0.33 | 5.91 |
| 2015 | -0.27 | 9.37 | 0.05 | -1.18 | 2.83 | -2.96 | 7.06 | -10.15 | 0.16 | 6.21 | -5.78 | -3.97 | 6.47 |
| 2016 | -4.54 | -0.66 | -1.36 | 8.86 | 6.72 | 1.30 | 3.69 | -5.94 | -2.36 | -5.82 | 4.44 | 3.28 | 5.52 |
| 2017 | -3.85 | 7.75 | -0.64 | -0.92 | -2.42 | 2.72 | -1.94 | 3.53 | 5.13 | -2.78 | 3.76 | -0.34 | 14.11 |
| 2018 | 1.64 | -1.40 | -0.43 | 4.45 | 2.53 | 0.08 | 9.91 | 3.99 | 6.51 | -2.76 | 6.68 | -5.07 | 24.09 |
| 2019 | -0.99 | 1.09 | -2.06 | -5.19 | 2.73 | 3.32 | -11.27 | -7.07 | -0.52 | 8.32 | 1.31 | 2.30 | -6.04 |
| 2020 | -3.86 | -10.89 | -6.42 | 20.82 | 2.47 | -7.75 | 15.18 | -1.44 | -0.49 | -2.43 | 12.59 | -6.59 | 3.20 |
| 2021 | -1.41 | -6.45 | 7.50 | 6.47 | -1.80 | 1.72 |
T 9.19 |
4.79 | -6.59 | 1.88 |
T 24.22 |
7.99 | 66.69 |
| 2022 | -6.28 | -11.54 |
T 13.14 |
-4.85 |
T 10.61 |
T 0.12 |
-2.68 | -10.63 | -6.17 |
T 5.44 |
5.31 | 0.33 | -6.61 |
| 2023 | -13.05 | -7.74 | 1.52 |
T -5.94 |
-1.99 |
T -3.52 |
T -1.61 |
T -0.65 |
-7.29 | -9.96 | -0.13 | -0.42 | -32.07 |
| 2024 |
T -8.91 |
-2.67 |
T 4.36 |
-7.58 |
T 5.45 |
-4.54 |
T 8.22 |
-5.35 |
T 2.26 |
-1.29 | -6.69 |
T 2.75 |
-10.76 |
| 2025 | -0.34 |
T 0.88 |
T -3.47 |
-0.53 |
T -1.84 |
3.32 | -6.99 |
T 5.41 |
2.00 |
T -9.41 |
T 4.38 |
T -1.46 |
-6.43 |
| 2026 |
T 5.00 |
3.71 | 3.01 | -6.48 | -0.57 | -6.05 | 4.73 |
T 12.15 |
11.48 |
T A T badge marks a Trendchange signal in that month. Hover for entry price.
Trendchange Signal History
The last 10 Trendchange signals for PFE:
| Date | Entry Price | Days Held | +10d | +20d | +30d | +60d |
|---|---|---|---|---|---|---|
| 03.08.26 | $25.03 | 6d | +7.03% | +0% | +0% | +0% |
| 22.01.26 | $26.10 | 28d | +2.61% | +2.91% | +4.44% | +7.55% |
| 15.01.26 | $25.89 | 2d | -0.04% | +0% | +0% | +0% |
| 01.12.25 | $25.27 | 14d | +2.3% | -0.91% | -0.91% | +0% |
| 26.11.25 | $25.71 | 2d | -0.54% | +0% | +0% | +0% |
| 17.11.25 | $25.08 | 0d | +0% | +0% | +0% | +0% |
| 02.10.25 | $27.08 | 6d | -9.45% | -9.45% | -9.45% | +0% |
| 14.08.25 | $25.11 | 18d | -0.16% | -1% | -1% | +0% |
| 13.08.25 | $25.16 | 0d | +0% | +0% | +0% | +0% |
| 28.05.25 | $23.18 | 37d | +4.83% | +4.66% | +11.22% | +7.25% |
Signal Statistics – Historical Edge
Calculated edge for PFE: 8.79%
| Range | N | 10d | 20d | 30d | 60d | Signal |
|---|---|---|---|---|---|---|
| 10-15% | 1 | +10.2% | +19.26% | +23.28% | +18.79% | Hold |
| 7-10% | 3 | +7.78% | +7.62% | +8.87% | +19.78% | Hold |
| 5-7% | 2 | +5.13% | +3.66% | +5.62% | +6.11% | Close |
| 3-5% | 6 | +3.92% | +5.25% | +7.83% | -0.12% | Close |
| 1-3% | 10 | +1.78% | +1.86% | +2.49% | +8.22% | Hold |
| 0-1% | 4 | +0.58% | -0.07% | +2.17% | +5.09% | Close |
| -1-0% | 9 | -0.37% | -0.21% | -0.26% | +0.79% | Neg |
| -3-1% | 11 | -1.87% | +1.2% | -0.68% | -2.75% | Neg |
| -5-3% | 3 | -4.04% | -4.39% | -4.39% | -5.92% | Neg |
| -10-7% | 1 | -9.45% | -9.45% | -9.45% | +0% | Neg |
Signal data as of August 21, 2026
Options Metrics
Gamma Exposure Timeline
Key GEX levels, Max Pain, and unusual activity across weekly and monthly expirations, plotted around the current spot price.
Key GEX levels, Max Pain, Anchor, Ceiling and unusual activity across 14-30 DTE, plotted around the current spot price.
Put and call pins mark strikes where dealer gamma exposure concentrates. The GEX flip strike is where dealer hedging shifts from stabilizing (positive gamma) to amplifying (negative gamma) price moves. Max Pain is the strike where the most options expire worthless. Dashed markers flag unusual options activity. Learn how to use these signals in our options strategy guides →
Strategy Setups – You Decide
Based on current options data, 2 setups match the current conditions. Each strategy has different risk/reward characteristics – the final decision is always yours.
All setups above are personal trade journal observations derived from options flow data. This is not financial advice. The decision to trade, and which strategy to use, is entirely yours.
View full options flow data and historical signals on the Options Flow Analysis Overview →
Valuation
| Metric | Value |
|---|---|
| Market Cap | $152.69 B |
| PE Ratio (TTM) | 35.25 |
| Forward PE | 9.25 |
| PEG Ratio | 2.55 |
| EV/EBITDA | 8.07 |
| Price/Sales | 2.40 |
| Price/Book | 1.79 |
| Beta | 0.28 |
Profitability
| Metric | Value |
|---|---|
| Gross Margin | 74.72% |
| Operating Margin | 27.88% |
| Net Margin | 6.80% |
| ROE | 5.01% |
| ROA | 5.78% |
Dividends
| Metric | Value |
|---|---|
| Annual Dividend | $1.72 |
| Forward Yield | 642.00% |
| Payout Ratio | 226.32% |
| Dividend Date | 2026-08-31 |
Analyst Consensus (26 Analysts)
| Metric | Value |
|---|---|
| Median Target | $28 |
| High Target | $35.75 |
| Low Target | $25 |
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
ETF Holdings
Pfizer Inc. is included in 2 ETFs tracked by StockBotty.